Ulka N Vaishampayan
Beverly S Mitchell M.D. Research Professor of Cancer Research
Professor of Internal Medicine and Ambulatory Care Clinical Chief
[email protected]

Available to mentor
Ulka N Vaishampayan
Clinical Professor
  • About
  • Center Memberships
  • Research Overview
  • Recent Publications
    • About

    Ulka Vaishampayan, MD, is a Professor of Internal Medicine and the Director of the Phase 1 Program and co-leader of the Translational and Clinical Research Program at the University of Michigan Rogel Cancer Center, Ann Arbor MI. She is also the Chair of the SWOG Advanced Renal Committee, a member of the National Cancer Institute (NCI) Renal Task Force, and a board member of the Michigan Society of Hematology/Oncology. She is the PI of the Kidney Cancer Research Consortium grant awarded by the Dept of Defense. Dr. Vaishampayan specializes in the treatment of genitourinary malignancies, including prostate cancer, bladder cancer, and renal cell carcinoma, and her research focuses on translational drug development and biomarkers. She has authored or coauthored numerous publications focusing on novel therapeutics for patients with genitourinary malignancies.

    Center Memberships
    • Center Member
      Rogel Cancer Center
    Research Overview

    Kidney cancer
    Prostate cancer
    Novel drug development
    Biomarker development
    Cancer Screening

    Recent Publications See All Publications
    • Journal Article
      Phase II Trial of Concurrent Nivolumab and Radiation Therapy for Muscle-Invasive Bladder Cancer of Older or Chemotherapy-Ineligible Patients.
      Vaishampayan UN, Heilbrun L, Vaishampayan N, Harper FWK, Shi D, Smith D, Green K, Guru K, Li Q, Kuettel M, Chatta G, Maier J, Dickow B, Moore TF, George S. Int J Radiat Oncol Biol Phys, 2024 Apr 1; 118 (5): 1472 - 1480. DOI:10.1016/j.ijrobp.2023.11.024
      PMID: 37981040
    • Journal Article
      Abstract A099: Preliminary pharmacodynamic characterization in patients with platinum-resistant ovarian cancer treated with nemvaleukin in combination with pembrolizumab
      Winer I, Vaishampayan UN, Gilbert L, Gandhi S, Velcheti V, Dalal R, Du Y, Donatelli S, Panchabhai S, Strauss JF, Piha-Paul S. Cancer Research, 2024 Mar 4; 84 (5_Supplement_2): a099 - a099. DOI:10.1158/1538-7445.ovarian23-a099
    • Journal Article
      A Global Phase II Randomized trial comparing Oral Taxane ModraDoc006/r to Intravenous Docetaxel in Metastatic Castration Resistant Prostate Cancer
      Vaishampayan UN, Keessen M, Dreicer R, Heath EI, Buchler T, Árkosy PF, Csöszi C, Wiechno P, Kopyltsov E, Orlov SV, Plekhanov A, Smagina M, Varlamov S, Shore ND. European Journal of Cancer, 2024 Mar; 114007 DOI:10.1016/j.ejca.2024.114007
    • Journal Article
      A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
      Juric D, Barve M, Vaishampayan U, Roda D, Calvo A, Jañez NM, Trigo J, Greystoke A, Harvey RD, Olszanski AJ, Opyrchal M, Spira A, Thistlethwaite F, Jiménez B, Sappal JH, Kannan K, Riley J, Li C, Li C, Gregory RC, Miao H, Wang S. Cancer Med, 2024 Mar; 13 (5): DOI:10.1002/cam4.6776
      PMID: 38501219
    • Journal Article
      Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review.
      Ghoreifi A, Vaishampayan U, Yin M, Psutka SP, Djaladat H. JAMA Oncol, 2024 Feb 1; 10 (2): 240 - 248. DOI:10.1001/jamaoncol.2023.5269
      PMID: 38095885
    • Journal Article
      Comparison of financial toxicity among patients with non-metastatic versus metastatic renal cell carcinoma.
      Staehler MD, Vaishampayan UN, Pal SK, Msaouel P, Derweesh I, Battle D. Journal of Clinical Oncology, 2024 Feb 1; 42 (4_suppl): 408 - 408. DOI:10.1200/jco.2024.42.4_suppl.408
    • Journal Article
      Development and application of a precision cell-free DNA (cfDNA) minimal residual disease (MRD) test to enable optimized treatment selection in patients with genitourinary (GU) cancers.
      Cooley D, Vaishampayan UN, Kaffenberger S, Drnek L, Johnson B, Lamb LE, Khazanov NA, Hovelson DH, Kwiatkowski K, Rhodes DR, Tomlins SA, Hafez K, Herrel LA, Montgomery JS, Gursky A, Udager AM, Morgan TM. Journal of Clinical Oncology, 2024 Feb 1; 42 (4_suppl): 473 - 473. DOI:10.1200/jco.2024.42.4_suppl.473
    • Journal Article
      Development and validation of a tumor tissue based multivariate biomarker for predicting angiogenesis inhibitor clinical benefit in renal cell carcinoma (RCC).
      Thomas SP, Vaishampayan UN, Johnson B, Lamb LE, Mowers J, Bulen BJ, Khazanov NA, Hovelson DH, Kwiatkowski K, Rhodes DR, Tomlins SA. Journal of Clinical Oncology, 2024 Feb 1; 42 (4_suppl): 467 - 467. DOI:10.1200/jco.2024.42.4_suppl.467